10-QPeriod: Q1 FY2011

ALNYLAM PHARMACEUTICALS, INC. Quarterly Report for Q1 Ended Mar 31, 2011

Filed May 5, 2011For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed its Form 10-Q for the period ending March 31, 2011. As an early-stage biopharmaceutical company, Alnylam's financial performance continues to be heavily influenced by its research and development activities and progress in advancing its pipeline of RNAi therapeutics. Investors should note that the company is not yet generating significant product revenue, and therefore, its financial results reflect substantial investments in drug development and operational expenses. The report details the company's financial position and operational results for the first quarter of 2011. Key areas to focus on include the company's cash burn rate, its progress in clinical trials, strategic partnerships, and its ability to secure necessary funding to support its ongoing development efforts. The absence of product sales means that profitability is not an immediate concern, but rather the efficient deployment of capital towards achieving key development milestones and regulatory approvals is paramount.

Financial Highlights

39 data points
Beta

Revenue

$20.90M

Net Income

-$16.29M

-77.9% Net Margin

EPS (Diluted)

$-0.38

Total Assets

$369.05M

Cash & Equivalents

$90.59M

Free Cash Flow

-$6.33M

Financial Statements
Beta
Revenue$20.90M
R&D Expenses$26.35M
Operating Expenses$36.57M
Operating Income-$15.68M
Net Income-$16.29M
EPS (Basic)$-0.38
Shares Outstanding (Basic)42.34M

Key Highlights

  • 1The company is operating at a net loss, consistent with its stage of development as a clinical-stage biopharmaceutical company investing heavily in R&D.
  • 2Cash and cash equivalents remain a critical component of the balance sheet, indicating the importance of ongoing financing and cash management.
  • 3Research and development expenses constitute a significant portion of the operating expenses, reflecting the company's commitment to advancing its RNAi therapeutic pipeline.
  • 4The report details the company's progress in its various therapeutic programs, which are key drivers of future value.
  • 5Alnylam continues to focus on strategic collaborations and partnerships to advance its drug candidates and leverage external expertise.
  • 6The company is actively managing its financial resources to fund its ongoing operations and development activities.

Frequently Asked Questions

As a clinical-stage biopharmaceutical company, Alnylam's primary sources of funding are typically equity financing, strategic collaborations, and potentially debt financing, rather than product sales, which are not yet generating revenue.

The net loss is expected for a company in Alnylam's development phase. It reflects significant investments in research and development necessary to bring new therapies to market. Investors should focus on the progress of the drug pipeline and the efficient use of capital rather than immediate profitability.

Investors should closely monitor Alnylam's cash and cash equivalents, burn rate (net cash used in operating activities), research and development expenses, and progress on key development milestones and partnerships. These metrics provide insight into the company's financial health and its ability to execute its strategic objectives.

Based on the information presented in this filing for the period ending March 31, 2011, Alnylam Pharmaceuticals is a clinical-stage company and is not yet generating significant product revenues. Its financial performance is driven by its R&D activities and pipeline development.